"Today's unclear laboratory question may be tomorrow's medicine." Evaluate India's support for basic scientific research in this light.

Basic science is research driven by curiosity, done without a product in view. mRNA research looked obscure for decades before it produced COVID-19 vaccines. Its value shows up late and in unexpected places, so it needs patient, assured funding. India has shown it intends to support such research, but its funding is still thin and leans towards quick returns.

Positives: building blocks of support

• ANRF Act, 2023: set up an apex body to give strategic direction to research, with ₹50,000 crore over five years [1].
• Rising rupee spend: GERD more than doubled, from ₹60,197 crore (2010–11) to ₹1,27,381 crore (2020–21) [2].
• State as anchor patron: the government provides about 64% of national R&D spending [1].
• RDI Fund (₹1 lakh crore): offers long-term, low-interest finance for high-risk deep-tech work [3].

Negatives: support that is impatient and thin

• Low intensity: GERD has been falling as a share of GDP since 2009–10. It reached 0.64% in 2020–21, against the 2% goal of the STI Policy 2013 [1]. China spends about 2.4% [2].
• Uncertain flows: the NRF's 2023–24 allocation of ₹2,000 crore was revised down to just ₹259 crore [1].
• Market tilt: about 80% of ANRF's money is expected from private sources [1]. Private firms prefer research close to the market. The RDI Fund lends money, and curiosity-driven science cannot repay a loan [3].
• Few researchers: India had about 260 researchers per million people (2015), against 1,602 in China [1].
• Narrow base: states contribute only about 7% of R&D spending [1].

Curiosity question → Basic insight → Applied research → Medicine
   [weakly funded]   [long, uncertain]   [RDI Fund, ANRF]   [market]

India funds the right side of the chain more than the left.

Verdict Support for basic science is partial. The institutions now exist, but the funding is neither large enough nor patient enough.

India now has both the institutions and the intent to support research, but its funding still favours results that come quickly. ANRF should ring-fence long-term, open-ended grants for university scientists, separate from deep-tech loans. States and higher-education institutions should be brought in, and GERD should rise steadily towards 2% of GDP. That would turn today's unclear laboratory questions into tomorrow's medicines and advance SDG 9.5, which calls for more scientific research and more researchers.